Welcome to our dedicated page for Climb Bio news (Ticker: CLYM), a resource for investors and traders seeking the latest updates and insights on Climb Bio stock.
Climb Bio, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated and B-cell mediated diseases. The CLYM news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Climb Bio communicates progress on its pipeline and corporate activities.
News about Climb Bio frequently highlights clinical development updates for its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody. Company announcements have covered initiation and enrollment of Phase 2 and Phase 1b/2a trials of budoprutug in primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, as well as a Phase 1 study of a subcutaneous formulation in healthy volunteers. Climb Bio also reports on preclinical and early clinical data, such as long-term follow-up results in pMN and nonhuman primate data for CLYM116 in IgA nephropathy.
Investors and followers can use this news feed to track regulatory milestones, including investigational new drug and clinical trial application clearances, initiation of Phase 1 studies for CLYM116, and updates on trial site activation and dosing progress. Corporate developments, such as leadership appointments, inducement equity grants under the company’s 2025 Inducement Plan, and participation in healthcare and biotechnology investor conferences, are also common topics in Climb Bio’s news flow.
By monitoring CLYM news on Stock Titan, readers gain a centralized view of Climb Bio’s disclosed clinical timelines, data presentations at scientific meetings, and strategic licensing arrangements related to its pipeline. This context can help users understand how the company’s immune-mediated disease programs are advancing through development.
Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's executive team will be presenting at this virtual event, which is scheduled to take place from April 7-10, 2025.
The presentation is specifically scheduled for April 10, 2025, at 8:45 a.m. ET. The format will include both a formal presentation and one-on-one investor meetings, providing opportunities for direct engagement with the company's leadership.
Climb Bio (NASDAQ: CLYM) reported its Q4 and full-year 2024 financial results, marking significant progress in its immune-mediated disease therapeutics pipeline. The company secured FDA clearance for clinical trials of budoprutug in three indications: Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE).
The company expanded its pipeline by in-licensing CLYM116, an anti-APRIL monoclonal antibody for IgA Nephropathy treatment. Financial highlights include a strong cash position of $212.5 million as of December 31, 2024, expected to fund operations through 2027. The company reported a net loss of $73.9 million for full-year 2024, compared to $35.1 million in 2023, with the increase primarily due to $51.7 million in acquired research and development expenses.
Climb Bio (Nasdaq: CLYM) announced that its executive team will participate in two upcoming investor conferences in March 2025. The company will attend the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 9:50 a.m. ET, featuring a formal presentation and one-on-one investor meetings. A webcast link is provided for virtual attendance.
Additionally, Climb Bio will participate in Leerink's Global Healthcare Conference 2025 on March 10, 2025, at 10:00 a.m. ET. This event will include a fireside chat format and one-on-one investor meetings, with a webcast link also available. The announcement was made from the company's Wellesley, Massachusetts headquarters on February 25, 2025.
Climb Bio (NASDAQ: CLYM) has appointed Dr. Perrin Wilson as Chief Business Officer. With 17 years of pharmaceutical and biotech industry experience, Dr. Wilson will lead the company's pre-commercial planning, communications, and business development efforts. Prior to joining Climb Bio, she served as Senior Vice President of Business Development and Strategy at Nuvalent and held key positions at Forma Therapeutics/Novo Nordisk.
Dr. Wilson's notable achievements include leading Forma's $1.1 billion acquisition by Novo Nordisk and Takeda's $5.2 billion acquisition of ARIAD. At Climb Bio, she will focus on advancing the company's pipeline, including key assets budoprutug and CLYM116, aimed at developing treatments for immune-mediated diseases.
Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The company's executive team will deliver a presentation on February 12, 2025, at 9:20 a.m. ET.
The virtual conference will feature both a formal presentation and one-on-one investor meetings. The event provides an opportunity for investors and stakeholders to gain insights into Climb Bio's developments and strategic initiatives.
Climb Bio (NASDAQ: CLYM) has secured an exclusive license agreement with Beijing Mabworks Biotech for CLYM116, an anti-APRIL monoclonal antibody, for development and commercialization outside Greater China. The agreement focuses on treating IgA nephropathy, the most common form of glomerulonephritis worldwide.
CLYM116 is engineered to prevent APRIL signaling through a novel mechanism, potentially offering advantages over current APRIL-targeted therapeutics. The company will make a $9 million upfront payment to Mabworks, with additional milestone payments and low- to mid-single digit tiered royalties on net sales.
The company reported $212.9 million in cash and equivalents as of December 31, 2024, expecting to fund operations through 2027. Initial preclinical data for CLYM116 is anticipated later in 2025.
Climb Bio (NASDAQ: CLYM) announced its upcoming addition to the NASDAQ Biotechnology Index (NBI) as part of the 2024 annual index reconstitution. The inclusion will be effective before market open on December 23, 2024. The NBI tracks performance of NASDAQ-listed biotechnology and pharmaceutical securities, using a modified capitalization-weighted methodology. Companies must meet specific eligibility criteria including minimum market capitalization, average daily trading volume, and public company seasoning requirements.
Climb Bio (Nasdaq: CLYM) reported its third quarter 2024 financial results and provided key business updates. Notable achievements include the FDA clearance of their IND for a Phase 1b clinical trial of budoprutug in systemic lupus erythematosus (SLE) and the appointment of Douglas Williams, Ph.D. as Chair of the Board of Directors. The company also expanded its management team by appointing Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing, and Controls.
Climb Bio's cash position was $217.9 million as of September 30, 2024, expected to fund operations through 2027. R&D expenses increased to $6.2 million, while G&A expenses rose to $5.5 million compared to the same period in 2023. The company reported a net loss of $8.9 million.
Future plans include advancing budoprutug for primary membranous nephropathy (pMN) and immune thrombocytopenia (ITP), with key milestones anticipated in 2025.
Climb Bio (Nasdaq: CLYM) has appointed Douglas E. Williams, Ph.D., as Chair of its Board of Directors, succeeding Andrew Levin, who will remain as a director. Dr. Williams brings over 30 years of executive leadership experience in biotechnology, having contributed to the development of several successful drugs and led multiple companies through development and commercialization. He previously served as President of R&D at Sana Biotechnology, CEO of Codiak BioSciences, and held executive positions at Biogen, ZymoGenetics, Seattle Genetics, Amgen, and Immunex. The company is focused on developing treatments for immune-mediated diseases, including their lead candidate budoprutug.
Climb Bio (Nasdaq: CLYM) has announced its executive team's participation in four major upcoming healthcare investor conferences. The schedule includes appearances at the Guggenheim Securities Healthcare Innovation Conference (Nov 11-12), Stifel Healthcare Conference (Nov 18-19), Piper Sandler Healthcare Conference (Dec 3-5), and Evercore ISI HealthCONx Conference (Dec 3-5). Each event will feature fireside chats and one-on-one investor meetings. All presentations will be webcast live and available for replay on the company's website under the Investors section.